Pharma BD Deal Intelligence

Watson Pharmaceuticals, Inc. / Actavis Group

2012 · Acquisition/Merger · $5.9B · Complete

Announcement Sentiment

Strongly positive

Watson Pharmaceuticals acquired Actavis Group for approximately EUR 4.25B (~$5.6-5.9B), creating the world's third-largest generics company with pro forma 2012 revenue of ~$8B. FTC required divestiture of 18 products to Sandoz/Par. Watson later renamed itself Actavis.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Apr 25, 2012
Closed Oct 31, 2012
Deal value $5.9B
Deal type Acquisition/Merger
Therapeutic area Generic pharmaceuticals (multi-therapeutic)
Indications Generic pharmaceuticals (multi-therapeutic)
Key assets Generics portfolio (>1,000 marketed products, 300 pipeline projects)
Mechanism Multiple (generics)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals